| Literature DB >> 32987040 |
Michele Aragona1, Cosimo Rodia2, Alessandra Bertolotto1, Fabrizio Campi1, Alberto Coppelli1, Rosa Giannarelli1, Cristina Bianchi1, Angela Dardano3, Stefano Del Prato4.
Abstract
AIMS: The aim of this study was to evaluate the effect the lockdown imposed during COVID-19 outbreak on the glycemic control of people with Type 1 diabetes (T1D) using Continuous (CGM) or Flash Glucose Monitoring (FGM).Entities:
Keywords: COVID-19; Flash glucose monitoring, continuous glucose monitoring; Lockdown; Time above range; Time below range; Time in range; Type 1 diabetes
Mesh:
Year: 2020 PMID: 32987040 PMCID: PMC7518840 DOI: 10.1016/j.diabres.2020.108468
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN: 0168-8227 Impact factor: 5.602
Main anthropometric and clinical characteristic of the Type 1 diabetes study population.
| Number of Patients | 63 |
| Sex Male (n – %) | 28 (44%) |
| Age (years) | 44 ± 12 |
| Diabetes duration (years) | 22 (12–32) |
| Body Mass Index (kg/m2) | 25 (22.8–28.5) |
| FGM/CGM (n – %) | 52/11 (82/18%) |
| MDI/CSII (n – %) | 35/28 (56/44%) |
| Nephropathy (n – %) | 9 (14%) |
| Neuropathy (n – %) | 6 (10%) |
| Retinopathy (n – %) | 16 (25%) |
| Coronary artery disease (n – %) | 2 (3%) |
| Hypertension (n – %) | 13 (21%) |
| Total Daily Insulin Dose (UI/die) | 40 (29–56) |
| Metformin (n – %) | 4 (6%) |
| ACEi/ARB (n – %) | 18 (29%) |
| Statins (n – %) | 13 (21%) |
| Acetylsalicylic acid | 8 (13%) |
FGM: Flash Glucose Monitoring; CGM: Continuous Glucose Monitoring; MDI: Multiple dose insulin; CSII: Continuous SubCutaneous Insulin Infusion; ACE.: Angiotensin Converting Enzyme inhibitors; ARB: Angiotensin Receptor Blocker.
Results of interest.
| P0 | P1 | P2 | P3 | ||
|---|---|---|---|---|---|
| †‡System use (%) | 91 ± 12 | 88 ± 12* | 85 ± 15* | 86 ± 13* | |
| ‡Scan/day (n) | 8 ± 6 | 8 ± 4 | 8 ± 5 | 9 ± 7 | |
| Average Glucose (mg/dl) | 165 ± 29 | 161 ± 31 | 161 ± 29 | 158 ± 31* | |
| GMI | 56 ± 8 | 54 ± 8 | 55 ± 7 | 53 ± 8** | |
| Coefficient of Variation (%) | 37.4 ± 6.0 | 37.6 ± 6.8 | 38.2 ± 5.9 | 38.3 ± 7.0 | |
| Time In Range % | 58 ± 15 | 62 ± 17* | 61 ± 15* | 62 ± 16* | |
| Time Above Range % | 38 ± 18 | 34 ± 18* | 34 ± 16* | 32 ± 17** | |
| Time Below Range % | 5 ± 6 | 5 ± 6 | 5 ± 5 | 6 ± 6 |
†Subjects using continuous glucose monitoring; ‡ Subjects using flash glucose monitoring; *p < 0.05; **p < 0.01 vs. P0.
Abbreviations: GMI: Glucose Management Indicator.
Fig. 1Bi-hourly daily glucose profile across the 4 periods of interest. *p < 0.05 or less vs. P0.